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THE HEALTH CARE COST OF SMOKING IN CANADA
Petit P1, Cremieux P2, Ouellette P3
1Groupe d’analyse, inc, Montreal, QC, Canada; 2Analysis Group,
Boston, MA, USA; 3Universite’ du Quebec a Montreal, Montreal, QC,
Canada
OBJECTIVES: Adverse health effects resulting from tobacco
smoking are associated with a signiﬁcant economic burden and
could be reduced through smoking-related health risk awareness
programs. The purpose of this paper is to measure health care
costs savings achievable by reducing smoking prevalence, and 
to simulate the costs and beneﬁts of an awareness program.
METHOD: A regression analysis was performed to link the
prevalence of smoking and the number of cigarettes smoked
daily by smokers to the incidence of: 1) lung cancer; 2) cancer
of the mouth; 3) heart disease; 4) cerebro-vascular disease; and
5) chronic obstructive pulmonary disease (COPD) in Canada
based on data from Statistics Canada (smoking prevalence) and
Health Canada (medical conditions). For each condition, the
reduction in the number of cases following a decrease in smoking
prevalence and in the number of cigarettes smoked was esti-
mated, and health care costs savings were calculated with con-
dition-speciﬁc unit cost estimates. The impact of a smoking
reduction program was simulated based on the impact of such
programs in the US, and its costs compared with resulting health
care costs savings. RESULTS: A one percent reduction in
smoking prevalence in Canada is associated with a reduction of
62 cases of cancer of the mouth, 98 lung cancer cases, 2835 heart
disease cases, 592 cerebrovascular disease cases, and 1263
COPD cases. These translate into health care cost savings of
$65.7CAN millions annually. Based on these estimates, a 10-year
smoking reduction program with costs and impact similar to that
implemented in California in the 1990s would have a net beneﬁt
ranging from CAN $1.7 billion to CAN $3.7 billion. CON-
CLUSIONS: Smoking is statistically related to many health con-
ditions and health care costs associated with these conditions can
be reduced through decreased smoking. Tobacco-reduction 
programs would yield substantial net beneﬁts to the Canadian
government.
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COST ANALYSIS OF LUNG CANCER TREATMENT IN TAIWAN
Yang CH, Chang CJ
National Taiwan University Hospital,Taipei,Taiwan
OBJECTIVE: Lung cancer is the leading cause of cancer death
in Taiwan. According to the statistics published by the Taiwan
Department of Health, 6555 patients died from lung cancer in
2001, and the mortality rate was 29.34 per 100,000 people. The
purpose of this study was to analyze the direct cost of lung cancer
management in Taiwan. METHODS: The claim database of the
Bureau of National Health Insurance in Taiwan was used for this
study, including the hospitalization and outpatient expenses for
2000 and 2001. The analyses comprised the average costs of hos-
pitalization or outpatient services for lung cancer patients.
RESULTS: Of the total hospitalization events for the year 2001,
56.86% were for chemotherapy administration (ICD-9-CM =
V581). The average number of in-hospital days was 4.8, and the
average cost for each event was NTD30, 648 (USD907.55)
(1USD = 33.77NTD). Febrile neutropenia, thrombocytopenia,
nausea and vomiting, neuropathy, and anemia were the common
causes of hospitalization in large-scale global phase III clinical
studies, but in Taiwan, only febrile neutropenia (144 events,
NTD 47,191 [USD 1,397.42]/event), and nausea and vomiting
(19 events, NTD19,361 [USD573.32]/event) were claimed in
2001. In addition, the average cost of outpatient chemotherapy
and non-chemotherapy service was NTD16,977 (USD502.72)
and NTD3,051 (USD90.35), respectively in 2001. CONCLU-
SION: This study adapts the database of the Taiwan Bureau of
National Health Insurance for the years 2000 and 2001 to a
descriptive analysis. The limitations of this research include the
complex nature of the disease, the multiple reasons for admis-
sion, and the imprecision of coding by health care providers.
Note: This study is based in part on data from the National
Health Insurance Research Database provided by the Bureau of
National Health Insurance, Department of Health and managed
by the National Health Research Institutes. The interpretation
and conclusions contained herein do not represent those of the
Bureau of National Health Insurance, Department of Health or
National Health Research Institutes.
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THE COST-EFFECTIVENESS ANALYSIS RECOMBINANT
HUMAN ERYTHROPOIETIN GROWTH FACTORS VS.
TRANSFUSION IN CHEMOTHERAPY CANCER PATIENTS
Tonnu IQ, Hay JW
USC School of Pharmacy, Los Angeles, CA, USA
Chemotherapy-induced anemia is currently treated with recom-
binant human erythropoietin growth factors (rHu-EGFs) or
transfusion. Currently, most studies ﬁnd that that blood trans-
fusion is more cost effective compared to rHu-EGFs due to the
high cost and relatively small quality of life (QOL) improvements
from the drugs. OBJECTIVES: To measure the cost effectiveness
of using blood transfusion vs. rHu-EGFs in chemotherapy-
treated cancer patients from the societal perspective and cost per
quality-adjusted life-year (QALY) approach. METHODS: A
spreadsheet model was used to evaluate the cost effectiveness of
erythropoietin (EPO) or darbepoietin (DARB) plus transfusion
when needed, compared to transfusion only. The model applied
clinical and QOL data from previous clinical trials and existing
literature, in an expected present value backwards induction
model using DEALE survival modeling to estimate cost per
QALY. In the base case, patients were 60 years old, weighed 60
kg and used the manufacturer’s recommended doses for
chemotherapy-related anemia. The model’s time horizon was one
year. A sensitivity analysis was performed to determine model
robustness. RESULTS: In the base case and relative to infusion
only, for each patient who received EPO, the cost per QALY was
$25,152, whereas, the cost per QALY was $45,646 for DARB.
The sensitivity analysis suggested that the model was only sen-
sitivity to QOL assumption, when the probability of infusion and
anemia was altered by 25%, the cost per QALY values for EPO
were $24,847–$25,473 and $21,419–$30,039, respectively.
Also, an 81% reduction in DARB dose or price would be needed
to equalize the cost of DARB treatment with that of EPO. CON-
CLUSIONS: This economic model demonstrates that treating
chemotherapy-related anemia using rHu-EGFs is more cost-
effective than transfusion only. Also, current clinical data sug-
gests that there are no signiﬁcant QALY differences between the
rHu-EGFs. Thus, EPO would be the dominant alternative.
PCN20
PRELIMINARY ECONOMIC ANALYSIS OF THE AMERICAN
CANCER SOCIETY GUIDELINES FOR MAMMOGRAPHY
SCREENING IN AVERAGE-RISK WOMEN UNDER 70 YEARS 
OF AGE
Zammit D, Hay J
University of Southern California, Los Angeles, CA, USA
The American Cancer Society Guidelines (ACS) recommends
women at average risk for breast cancer to begin annual 
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mammography at age 40. OBJECTIVE: To develop a prelimi-
nary model to evaluate the cost-effectiveness of these guidelines,
using similar assumptions and clinical trial evidence sources for
the breast cancer mortality beneﬁt as the ACS. METHODS:
Interventions: Annual mammography until age 70 vs. no annual
mammography. Design: Age-speciﬁc discounted lifetime costs
and discounted quality-adjusted life expectancy were estimated
for each intervention, and the incremental cost-effectiveness ratio
(ICER) calculated. Life-expectancy estimates were generated by
Markov model simulation starting from age 40. Direct costs
included the management of early-stage and invasive breast
cancer, and the costs of mammography and the workup of a pos-
itive result. Indirect costs accounted for the time spent getting
mammograms. BC management costs with and without mam-
mography were assumed to be the same. Time Horizon: Life-
time. Perspective: Societal. Target Population: The model was
estimated in white females aged 40 and over. Data Sources: RCT
Meta-analysis evidence sources used by the ACS, SEER data for
BC mortality and life expectancy, NCHS life-tables data, studies
of mammography performance, and quality of life/health utility
studies. Sensitivity analysis was done to the discount rate, costs,
sensitivity of mammography and costs of mammography.
RESULTS: Base-Case Analysis: The ICER for annual mammog-
raphy until age 70 was extremely high with a minimum value of
$347,442/QALY at age 60. Annual mammography until age 80
was slightly more cost-effective, ranging from $424,058/QALY,
$323,893/QALY and $271,773/QALY at ages 40, 55, and 70
respectively. CONCLUSIONS: Annual mammography starting
from age 40 may turn out to be a very expensive policy. However,
the economic model has some limitations: the mammography
intervention may be associated with different BC management
costs; and the data sources for BC mortality reduction with
mammography have been widely disputed.
CANCER
CANCER—Quality Of Life/Patient Preferences
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SHORT-TERM PSYCHOSOCIAL COUNSELING FOR PATIENTS
WITH NEWLY-DIAGNOSED PROSTATE CANCER
Sadetsky N1, Kneier A1, Latini DM1, Knight S2, Loi J1, Carroll PR1
1University of California, San Francisco, CA, USA; 2San Francisco VA
Medical Center, San Francisco, CA, USA
OBJECTIVE: Prostate cancer can have signiﬁcant physical, psy-
chological, and social impact on patients, particularly early in
the treatment course. While psychological intervention during
oncologic care has been shown to improve all aspects of well-
being, few studies have focused on men diagnosed with prostate
cancer or have targeted the period between diagnosis and treat-
ment. We evaluated the efﬁcacy of an innovative, brief psy-
chosocial counseling program delivered to men before and after
prostate cancer treatment. METHODS: One hundred thirty-two
men diagnosed with prostate cancer were randomly assigned to
either intervention (n = 69) or control (n = 63) groups. Partici-
pants completed the Proﬁle of Mood States (POMS), Index of
Coping Responses (ICR), and scales measuring general and
disease-speciﬁc HRQOL, at baseline (before treatment com-
menced) and at months 3 and 12. Both groups received standard
medical care; and intervention participants received 2 sessions of
counseling before treatment and one session 4 to 6 weeks after
treatment completion. RESULTS: Intervention effects were eval-
uated using a mixed model analysis, adjusting for cancer treat-
ment (radiation or surgery) and time. There were no signiﬁcant
differences between groups at baseline on the demographic or
psychosocial measures. In the mixed model, intervention partic-
ipants reported signiﬁcant improvements over time on three out-
comes: Vigor (POMS; p < 0.05) and Information Seeking and
Affective Regulation (ICR; p < 0.01 and p < 0.05, respectively).
CONCLUSIONS: While the brief intervention did not appear to
inﬂuence HRQOL, or prostate-speciﬁc symptoms, it improved
energy level and coping responses, particularly those relevant to
managing information and emotions. These coping strategies
may be especially important given the decision-making and treat-
ment initiation tasks of early prostate cancer care. Source of
ﬁnancial support: California Cancer Research Program Grant
#97–12013.
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THE EUROPEAN ORGANIZATION FOR RESEARCH AND
TREATMENT OF CANCER QUALITY OF LIFE CORE
QUESTIONNAIRE (EORTC QLQ-C30): VALIDATION OF
ENGLISH VERSION IN SINGAPORE
Xie F, Luo N, Li SC
National University of Singapore, Singapore, Singapore
OBJECTIVE: To assess the validity and reliability of EORTC
QLQ-C30 in patients with cancer in Singapore. METHODS: A
total of 62 patients at Cancer Center of National University
Hospital were asked to complete independently QLQ-C30 and
a generic questionnaire (SF-36). The sociodemographic data
were obtained simultaneously. RESULTS: The QLQ-C30
demonstrated good internal reliability for most scales with 
Cronbach’s alpha more than 0.7 except cognitive functioning,
physical functioning, and nausea and vomiting scale. The major-
ity of item-scale Pearson’s coefﬁcients (corrected for overlap)
were more than 0.4 and higher as opposed to that between the
item and competing scales in the same instrument. All function-
ing scales in QLQ-C30 had strong correlations with the scales
measuring the similar aspect of QoL in SF-36. The correlation
coefﬁcients among all scales were signiﬁcant but modest (ranging
from an absolute value of 0.23 to 0.65). CONCLUSION: In our
study, QLQ-C30 could be considered reliable and valid using to
evaluate health related quality of life (HRQoL) in cancer patients
in Singapore.
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XEROSTOMIA SYMPTOMS: A NEWLY DEVELOPED PATIENT
REPORTED OUTCOMES QUESTIONNAIRE
Colwell HH1, Pritchard ML1, Hill JC1, Sneeringer RK1, Miller DP1,
Calhoun EA2
1Ovation Research Group, Highland Park, IL, USA; 2Northwestern
University, Chicago, IL, USA
OBJECTIVE: The majority of head and neck cancer (HNC)
patients undergoing radiation experience xerostomia (dry
mouth) which can range from mild to severe, even after com-
pletion of treatment. Its impact on quality of life (QoL) can be
signiﬁcant. The objective of this study was to evaluate the psy-
chometric properties of a new questionnaire developed to assess
the impact of xerostomia on QoL. METHODS: Data were
obtained from radiation patients (RP) participating in the Eval-
uating Cytoprotection Health Outcomes (ECHO) Registry.
ECHO, a prospective, longitudinal study of patients receiving
amifostine prior to radiation and/or chemotherapy, collects clin-
ical and outcomes information. All RP complete a questionnaire,
including the Functional Assessment of Cancer Therapy-General
(FACT-G) and a new questionnaire assessing xerostomia symp-
toms (XSQ) at baseline, 6-weeks (completion of radiation), and
at 6 weeks, 3 months, and 6 months post treatment. RESULTS:
A total of 104 with HNC, 43 with non-small cell lung cancer
(NSCLC), and 38 with other cancer completed the questionnaire.
